Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Reply to Mallone R [letter]
- Author(s)
- Phillip, M; Achenbach, P; Addala, A; Albanese-O'Neill, A; Battelino, T; Bell, KJ; Besser, REJ; Bonifacio, E; Colhoun, HM; Couper, JJ; Craig, ME; Danne, T; de Beaufort, C; Dovc, K; Dutta, S; Ebekozien, O; Elding Larsson, H; Frohnert, BI; Gallagher, MP; Greenbaum, CJ; Griffin, KJ; HAGOPIAN, W; Haller, MJ; Hendriks, E; Holt, RIG; Ismail, HM; Jacobsen, LM; Kolb, LE; Kordonouri, O; Lange, K; Lash, RW; LERNMARK, A; Libman, I; Lundgren, M; Maahs, DM; Marcovecchio, ML; Mathieu, C; Oron, T; Patil, SP; Rewers, MJ; Rich, SS; Schatz, DA; Schulman-Rosenbaum, R; Simmons, KM; Sims, EK; Skyler, JS; Speake, C; Steck, AK; Tonyushkina, KN; Veijola, R; Wentworth, JM; Wherrett, DK; Wood, JR; ZIEGLER, AG; DiMeglio, LA;
- Details
- Publication Year 2025-04,Volume 68,Issue #4,Page 892-895
- Journal Title
- Diabetologia
- Publisher
- Springer
- Keywords
- Autoantibodies; Glucose monitoring; Prevention; Type 1 diabetes
- Research Division(s)
- Immunology
- PubMed ID
- 39934371
- Publisher's Version
- https://doi.org/10.1007/s00125-024-06350-x
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-09-23 11:15:48
Last Modified: 2025-09-23 11:16:09